Abbott Launches its Molecular Test to Detect COVID-19 and Receives the US FDA’s Emergency Use Authorization

 Abbott Launches its Molecular Test to Detect COVID-19 and Receives the US FDA’s Emergency Use Authorization

Abbott Launches its Molecular Test to Detect COVID-19 and Receives the US FDA’s Emergency Use AuthorizationAbbott Launches its Molecular Test to Detect COVID-19 and Receives the US FDA’s Emergency Use Authorization

Shots:

  • The US FDA has issued EUA for Abbott’s molecular test for COVID-19 and will be used on the m2000 RealTime system which is currently available in hospitals and molecular laboratories in the US
  • Abbott will be working with health systems and government authorities to deploy additional m2000 systems and is scaling up production at its US site to reach capacity for 1M test/ week by the end of March
  • Abbott’s m2000 molecular platform utilizes PCR technology, amplifying a single piece of DNA to diagnose the patients accurately

Click here ­to­ read full press release/ article | Ref: Abbott | Image: Fierce Biotech

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post